Archive for March, 2008
The Last Taboo: Opening The Door On The Global Sanitation Crisis
Sandy Cairncross
In this edition of Audio News, presented by Peter Goodwin,
Sandy Cairncross (London School of Hygiene and Tropical Medicine), Maggie Black (Earthscan), and Girish Menon (Water Aid) talk about:
The Last Taboo: Opening The Door On The Global Sanitation Crisis
- a book by Maggie Black and Ben Fawcett, published by Earthscan with UNICEF.
Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
Giorgio Scagliotti
Robert Pirker
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.
Front Line Therapy in Non-Small Cell Lung Cancer
Nick Thatcher
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein.
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold
Nick Thatcher
Nick Thatcher, Christie Hospital, Manchester
Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.
Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
Robert Pirker
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
Lung Cancer Screening: Wait for Prospective Study Findings!
Ugo Pastorino
Even the most sophisticated and powerful detection method for lung cancer detection, spiral CT, is still unproven in the context of mass screening for lung cancer. At the conference in Turin, Ugo Pastorino, urged delegates to wait for the findings of the large randomized studies of spiral CT now being conducted before deciding whether to use this technique. He discussed his group’s findings with Peter Goodwin.
Audio Journal of Oncology in Advance - March 15th, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Audio Journal of Oncology in Advance - March 1st, 2008
Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Richard Stone
George Canellos
Dasatinib: Durable Responses in Chronic Myeloid Leukemia
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.
Phil Edwards, London School of Hyugiene and Tropical Medicine
